PDS Biotechnology shares surge 19.29% premarket on positive clinical trial updates and improved financials.

PDS Biotechnology surged 19.29% in premarket trading following its Q4 2025 earnings call, where the company highlighted strong clinical progress, including a final median overall survival of 39.3 months in the VERSATILE-002 trial for HPV16-positive head and neck cancer. The trial amendment to VERSATILE-003, incorporating progression-free survival as a primary endpoint, is expected to accelerate regulatory timelines. The company also noted reduced net losses and operating expenses compared to 2024, demonstrating improved financial discipline. Positive sentiment was further fueled by PDS0101’s favorable tolerability profile and potential for accelerated approval, despite ongoing R&D challenges and lack of 2026 guidance.